Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case

Eur J Gastroenterol Hepatol. 2004 Jun;16(6):627-30. doi: 10.1097/00042737-200406000-00018.


Treatment with the anti-tumour necrosis factor alpha chimeric monoclonal antibody infliximab is highly effective in the treatment of refractory and fistulising Crohn's disease. Infliximab has been tolerated well, with minimal and short-lived adverse effects. The likelihood of severe reactions to infliximab, such as acute and delayed hypersensitivity infusion reactions, is small; nevertheless, if they do occur, they are life-threatening. We report a case of an anaphylaxis-like reaction in a 22-year-old female with long-standing Crohn's disease. The patient was treated successfully with adalimumab, a fully human anti-tumour necrosis factor alpha monoclonal antibody. Follow-up demonstrated mucosal healing and normalisation of elevated pro-inflammatory cytokine transcripts.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Adult
  • Anaphylaxis / chemically induced*
  • Anaphylaxis / drug therapy
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Crohn Disease / drug therapy*
  • Female
  • Gastrointestinal Agents / adverse effects*
  • Humans
  • Infliximab


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Gastrointestinal Agents
  • Infliximab
  • Adalimumab